Phase III data EVOLVE-ing nicely for Omthera's Epanova
This article was originally published in Scrip
Executive Summary
Top-line data from a Phase III trial of Omthera Pharmaceuticals' lead product, the prescription-grade omega-3 fatty acid candidate, Epanova, show that it met its primary endpoint at all three doses tested, paving the way for a US NDA filing later this year.